Gabriel Brooks
Insider (Form 4 reporting owner): Chief Medical Officer CIK 1997809Name as filed: Brooks GabrielIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 21 Oct 2024, sold $337K in 7 sales (5 under a 10b5-1 plan set in advance) of Solid Biosciences.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Solid Biosciences SLDB | Chief Medical Officer | 21 Oct 2024 | 19 Oct 2026 | – | 7$337K |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | too few trades4 trades | too few trades4 trades | too few trades3 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 4 | $288K | -$288K |
| 2025 | – | – | 2 | $30K | -$30K |
| 2024 | – | – | 1 | $19K | -$19K |
Every trade
7, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 19 Oct 2026 | Solid Biosciences SLDB | Sellafter exercising options | 4,374 | $5.62 | $25K | 10b5-1 plan | Form 4filed 20 Oct 2026 |
| 18 Feb 2026 | Solid Biosciences SLDB | Sellafter exercising options | 0 | Not filed | Not filed | 10b5-1 plan | Form 4filed 18 Feb 2026 |
| 4 Feb 2026 | Solid Biosciences SLDB | Sell | 12,616 | $6.44 | $81K | 10b5-1 plan | Form 4filed 6 Feb 2026 |
| 2 Feb 2026 | Solid Biosciences SLDB | Sellafter exercising options | 28,335 | $6.44 | $182K | 10b5-1 plan | Form 4filed 2 Feb 2026 |
| 20 Oct 2025 | Solid Biosciences SLDB | Sellafter exercising options | 2,895 | $5.96 | $17K | No | Form 4filed 21 Oct 2025 |
| 14 Feb 2025 | Solid Biosciences SLDB | Sellafter exercising options | 3,256 | $3.96 | $13K | 10b5-1 plan | Form 4filed 18 Feb 2025 |
| 21 Oct 2024 | Solid Biosciences SLDB | Sellafter exercising options | 2,923 | $6.50 | $19K | No | Form 4filed 22 Oct 2024 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.